title: Morphologic changes of apoptosis induced in human chronic myelogenous leukemia "blast" cells by SC41661A (Searle), a selective inhibitor of 5-lipoxygenase.
abstract: Several inhibitors of the arachidonic acid-metabolizing enzyme, 5-lipoxygenase reduce proliferation of hematopoietic and non-hematopoietic cells and cell lines and some cells undergo limited differentiation. Cells were cultured from patients with chronic myelogenous leukemia in "blast" crisis with the selective inhibitor of 5-lipoxygenase, SC41661A[3-(3,5-bis(1,1-dimethyl)-4-hydroxyphenyl)hiol]-N-me thyl-N-[2-(2- phridinyl-propanamide)]. Cells cultured for 3 to 5 days with 40 microM SC41661A exhibited reduced cellular numbers along with ultrastructural changes and DNA laddering characteristic of apoptosis. Similar culture conditions reduced proliferation of U937 monoblastoid cells. In U937 cells, the ultrastructural features of apoptosis were not observed at 72 hours, when DNA laddering was present and cell numbers were reduced, but was present after 144 hours of culture. Dissociation between certain morphologic and biochemical sequelae of apoptosis has been described in other systems. These observations are of interest since the induction of apoptosis in dividing chronic myelogenous leukemia (CML) cells by a non-cytotoxic agent suggests paradigmatically new sites for therapeutic intervention.
authors.affiliation: Department of Medicine, Rush Medical College, Chicago, IL 60612, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Anderson
authors.forename: T M
authors.initials: TM
authors.lastname: Seed
authors.forename: J
authors.initials: J
authors.lastname: Peng
authors.forename: A
authors.initials: A
authors.lastname: Jajeh
authors.forename: J
authors.initials: J
authors.lastname: Meng
authors.forename: J E
authors.initials: JE
authors.lastname: Harris
mesh_terms: D000577:Amides / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D016923:Cell Death / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002843:Chromatin / Q000187:drug effects / Q000648:ultrastructure; D004249:DNA Damage / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000577:Amides; D002843:Chromatin; D004273:DNA, Neoplasm; D016859:Lipoxygenase Inhibitors; D011725:Pyridines; C081292:SC 41661A